SLN (Silence Therapeutics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


SLN Silence Therapeutics PLC SLN
44 GF Score
Price $9.99
GF Value $0.21
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Silence Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Silence Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

SLN vs CRBP, TTRX, AGEN: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Silence Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


SLN
44GF Score
Silence Therapeutics PLC SLN
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Silence Therapeutics (SLN) Overvalued in 2026?

Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued. The current stock price of $9.99 is trading 4657.1% above its estimated GF Value™ of $0.21. GuruFocus considers Silence Therapeutics to be Significantly Overvalued.

Key valuation signals for SLN:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.21 vs. price of $9.99 (4657.1% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Silence Therapeutics Business Description

Other Exchanges SLNCF:USAXRP2:Germany
Address 12 Hammersmith Grove, London, GBR, W6 7AP
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
44GF Score

Get the complete analysis for SLN

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.99
Price
$0.21
GF Value